Hidradenitis Suppurativa: Medical and Procedural Treatment
hidradenitis suppurativaNext Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Amit Garg, professor and founding chairman of the department of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Garg explains why it’s an exciting time in hidradenitis suppurativa, and how clinicians are using existing therapies in innovative ways. Watch as he explains the imp …
hidradenitis suppurativa
JDD April 2023 Issue Highlights
The April issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, features, and case reports,  with topics ranging from hormonal therapy in hidradenitis suppurativa, private equity in dermatology, vitiligo and its associated comorbidities, novel topical products for facial dyschromia, and many more.  Check out this month’s issue highlights straight …
Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy
psoriasis Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment Danielle Rinck MDa, Elaine Siegfried MDb aBeth Israel Deaconess Medical Center, Boston, MA | bSaint Louis University School of Medicine, St. Louis, MO J Drugs Dermatol. 2022;21(8):897-899. doi:10.36849/JDD.6888   A previously healthy 3-year-old boy presented to our Pediatric Derm …
psoriasis
Apremilast Therapeutic Cheat Sheet
apremilastApremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica …
apremilast
JDD February 2023 Issue Highlights
The February issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and brief communications exploring topics such as efficacy and safety of 1% clascoterone cream in patients aged ≥12 years with acne vulgaris, dupilumab’s impact on atopic dermatitis among adolescent and adult patients, development and validation of a photonumeric scale …
error

Enjoy this blog? Please spread the word :)